Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.

CSL has started construction on a major expansion of its advanced manufacturing facility in Illinois to increase output of plasma-derived therapies. The Illinois project is expected to support higher production capacity and new skilled jobs in the U.S. healthcare manufacturing sector. CSL subsidiary Seqirus has renewed a Canadian agreement to supply millions of cell-based influenza vaccine doses for pandemic preparedness. The renewed Canadian contract reinforces CSL's role in critical vaccine supply chains across North America.

CSL (ASX:CSL), trading at A$142.22, is moving ahead with large scale investment in its physical manufacturing footprint while also locking in long term vaccine demand through Seqirus. These developments arrive after a period of pressure on the share price, with the stock showing a 21.2% decline over the past 30 days and a 43.7% decline over the past year. For investors, the contrast between operational expansion and recent market performance is an important part of the current CSL story.

The Illinois expansion and the renewed Canadian pandemic vaccine contract highlight how CSL is positioning its plasma and vaccine businesses within global health supply chains. If you are tracking ASX:CSL, these moves may be useful markers when assessing how the company is aligning its capacity, product mix and public health partnerships with future healthcare needs.

Stay updated on the most important news stories for CSL by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on CSL.ASX:CSL Earnings & Revenue Growth as at Mar 2026

📰 Beyond the headline: 4 risks and 3 things going right for CSL that every investor should see.

Quick Assessment

✅ Price vs Analyst Target: At A$142.22, CSL trades about 33% below the A$211.83 analyst price target range midpoint. ✅ Simply Wall St Valuation: Simply Wall St estimates CSL is trading 51.1% below its fair value, suggesting a marked valuation gap. ❌ Recent Momentum: The share price has fallen 21.2% over the past 30 days, showing weak short term sentiment.

There is only one way to know the right time to buy, sell or hold CSL: review a detailed analysis. Head to Simply Wall St's company report for the latest analysis of CSL's Fair Value.

Key Considerations

📊 The U.S. plant build and Canadian vaccine contract point to CSL committing capital to long life plasma and vaccine capacity while the share price is under pressure. 📊 Watch execution on the Illinois project, any disclosed returns on this investment, and updates on vaccine volumes tied to the Canadian agreement. ⚠️ With high debt, a 9.1% profit margin and profits affected by large one off items, funding and ramp up risks around new facilities deserve close attention.

Story Continues

Dig Deeper

For the full picture including more risks and rewards, check out the complete CSL analysis. Alternatively, you can check out the community page for CSL to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include CSL.AX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments